Latteyer S, et al. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. Endocrine 2016 Dec;54(3):733-741. doi:10.1007/s12020-016-1080-9
